Anti-Laminin 332-Type Mucous Membrane Pemphigoid

Biomolecules. 2022 Oct 12;12(10):1461. doi: 10.3390/biom12101461.

Abstract

Anti-laminin (LM) 332-type mucous membrane pemphigoid (MMP) is a rare autoimmune bullous disease and was originally discovered as anti-epiligrin cicatricial pemphigoid. Anti-LM332-type MMP has clinical manifestations similar to those of other types of MMP and can only be distinguished through the detection of circulating autoantibodies against LM332. Our group and others have established a number of immunological methods with varying sensitivity and specificity for detection of anti-LM332 autoantibodies; however, none of the established methods has been widely used for clinical diagnosis. There is currently no unified standard treatment, and it is very difficult to completely cure anti-LM332-type MMP. In addition, an increasing body of evidence suggests that there may be a strong correlation between anti-LM332-type MMP and tumors. In this article, we review the current progression of diagnosis and treatment of anti-LM332-type MMP, as well as the possible correlation between anti-LM332-type MMP and tumors.

Keywords: cicatricial pemphigoid; diagnosis; laminin 332; mucous membrane pemphigoid; treatment; tumor.

Publication types

  • Review

MeSH terms

  • Autoantibodies
  • Autoimmune Diseases*
  • Humans
  • Laminin / immunology
  • Mucous Membrane / pathology
  • Neoplasms*
  • Pemphigoid, Benign Mucous Membrane* / diagnosis
  • Pemphigoid, Benign Mucous Membrane* / pathology
  • Pemphigoid, Bullous*

Substances

  • Autoantibodies
  • Laminin

Grants and funding

This research received no external funding.